NCT03868527

Brief Summary

To identify the diagnostic and therapeutic approach (efficacy and toxicity) of patients with lymphoid malignant hemopathy who are managed in the hematology department.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
13,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2003

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2003

Completed
16.2 years until next milestone

First Submitted

Initial submission to the registry

February 26, 2019

Completed
13 days until next milestone

First Posted

Study publicly available on registry

March 11, 2019

Completed
6.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

March 11, 2019

Status Verified

March 1, 2019

Enrollment Period

23 years

First QC Date

February 26, 2019

Last Update Submit

March 8, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Progression-free survival

    Period between the end of the first treatment and the first confirmed relapse of lymphoma of patients who have received treatment to treat their lymphoma.

    730 days

Study Arms (1)

Hematological diseases

Cohort of patients followed for lymphoid malignant hemopathy in Lyon Sud Hospital

Other: Data collection

Interventions

Data collection for biostatistical analysis about hematological diseases

Hematological diseases

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients followed for lymphoid malignant hemopathy in Lyon Sud Hospital

You may qualify if:

  • \- Patients followed for hematological diseases in Lyon Sud Hospital

You may not qualify if:

  • \- Patients who doesn't have hematological diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Lyon Sud

Pierre-Bénite, France

RECRUITING

MeSH Terms

Conditions

Hematologic Diseases

Interventions

Data Collection

Condition Hierarchy (Ancestors)

Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Epidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Gilles Salles, MD

    Hospices Civils de Lyon

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Gilles Salles, MD

CONTACT

Marion Choquet

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 26, 2019

First Posted

March 11, 2019

Study Start

January 1, 2003

Primary Completion

December 31, 2025

Study Completion

December 31, 2025

Last Updated

March 11, 2019

Record last verified: 2019-03

Locations